ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Azitra Inc

Azitra Inc (AZTR)

0.584
-0.016
( -2.67% )
Updated: 13:35:38

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
0.584
Bid
-
Ask
-
Volume
317,164
0.57 Day's Range 0.6415
0.492 52 Week Range 68.40
Market Cap
Previous Close
0.60
Open
0.619
Last Trade
2000
@
0.584
Last Trade Time
13:35:38
Financial Volume
$ 191,558
VWAP
0.603971
Average Volume (3m)
3,220,714
Shares Outstanding
7,625,056
Dividend Yield
-
PE Ratio
-0.36
Earnings Per Share (EPS)
-1.66
Revenue
686k
Net Profit
-12.64M

About Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company. The Company is focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. Its platform includes a microbial library ... Azitra Inc is an early-stage clinical biopharmaceutical company. The Company is focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. Its platform includes a microbial library comprised of approximately 1,500 bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its product ATR-12 is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its product ATR-04 is a genetically modified strain of S. epidermidis for treating the papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Azitra Inc is listed in the Pharmaceutical Preparations sector of the American Stock Exchange with ticker AZTR. The last closing price for Azitra was $0.60. Over the last year, Azitra shares have traded in a share price range of $ 0.492 to $ 68.40.

Azitra currently has 7,625,056 shares outstanding. The market capitalization of Azitra is $4.58 million. Azitra has a price to earnings ratio (PE ratio) of -0.36.

AZTR Latest News

Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the U.S. Food and Drug...

Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Azitra, Inc. (NYSE American: AZTR), a precision dermatology company announced that it announced today that Travis Whitfill, COO, will present an overview of the Company at the H.C. Wainwright...

Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome

Azitra, Inc. (NYSE American: AZTR), a precision dermatology company, announced that it has initiated dosing the first patient in its Phase 1b clinical trial evaluating ATR-12 for the treatment of...

Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors

New investigational new drug (IND) application cleared to proceed by the US FDA for a Phase 1/2 clinical study of ATR-04 for moderate to severe EGFR inhibitor (β€œEGFRi”) associated dermal...

Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome

Azitra, Inc. (NYSE American: AZTR), a precision dermatology company announced that it has successfully screened the first patient in its Phase 1b clinical trial evaluating ATR-12 for the...

Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.0244.285714285710.560.6670.5355674250.59332759CS
4-0.12-17.04545454550.7040.760.525206650.66479651CS
12-3.139-84.31372549023.723120.49232207142.57560176CS
26-6.445-91.69156352257.029120.49224302013.90205149CS
52-53.116-98.912476722553.768.40.49213243894.44018446CS
156-127.216-99.5430359937127.8155.40.49210608455.03656688CS
260-127.216-99.5430359937127.8155.40.49210608455.03656688CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SGNSigning Day Sports Inc
$ 0.514
(295.69%)
495.64M
ATCHAtlasClear Holdings Inc
$ 0.1755
(23.24%)
644k
MSTUT Rex 2X Long MSTR Daily Target ETF
$ 30.89
(21.06%)
975.52k
RYDERyde Group Ltd
$ 1.365
(20.80%)
7M
SOXLDirexion Daily Semiconductor Bull 3X Shares
$ 36.0219
(15.68%)
82.12M
MSTZT Rex 2X Inverse MSTR Daily Target ETF
$ 18.79
(-23.16%)
24.08k
EFSH1847 Holdings LLC
$ 1.6633
(-16.84%)
110.74k
SOXSDirexion Daily Semiconductor Bear 3X Shares New
$ 21.035
(-15.59%)
61.69M
HCWCHealthy Choice Wellness Corp
$ 2.9643
(-15.31%)
182.26k
MMAAlta Global Group Limited
$ 2.8762
(-12.84%)
10.11k
SGNSigning Day Sports Inc
$ 0.514
(295.69%)
485.33M
SOXLDirexion Daily Semiconductor Bull 3X Shares
$ 36.0219
(15.68%)
77.77M
SOXSDirexion Daily Semiconductor Bear 3X Shares New
$ 21.035
(-15.59%)
61.69M
SPXSDirexion Daily S&P 500 Bear 3X Shares New
$ 6.8193
(-5.68%)
33.96M
SPYSPDR S&P 500
$ 571.935
(1.88%)
33.69M

AZTR Discussion

View Posts
herbied47 herbied47 2 days ago
Should be getting an update soon. Strong buy right here with this kind of low float.
πŸ‘οΈ0
Viewmont Viewmont 3 weeks ago
https://finance.yahoo.com/news/azitra-announces-first-patient-dosed-123000947.html
👍️ 1
Viewmont Viewmont 3 weeks ago
Moving after hours, what's up?
πŸ‘οΈ0
herbied47 herbied47 4 weeks ago
Press releases left and right. Sabby closing their short position the other day was the first clue. This will trade not
north of $3.00 soon! Load up!
πŸ‘οΈ0
glenn1919 glenn1919 4 weeks ago
AZTR................................https://stockcharts.com/h-sc/ui?s=AZTR&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
mikey4 mikey4 4 weeks ago
Shoulda dumped, looked a gift horse in the mouth and said β€œno thanks.”
πŸ‘οΈ0
herbied47 herbied47 4 weeks ago
Gap fill. Going back up! $1.50 open
πŸ‘οΈ0
Invest-in-America Invest-in-America 4 weeks ago
AZTR; Be very careful --- merely PHASE-1, & a RARE skin disorder to boot. (Ain't goin' nowhere.)
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 4 weeks ago
Nice thanks
πŸ‘οΈ0
mikey4 mikey4 1 month ago
Another dilution guaranteed

This is the easiest to estimate as the average duration for each phase is known. Roughly these are;

*Discovery - 3 years

*Pre-clinical - 1 year

*Phase I - 1/1.5 years

*Phase II - 1.5/2.5 years

*Phase III - 2/4 years

*Filing - 0.75 years

These are rough of course. In particular orphan drugs tend to progress faster as they can combine clinical phases.
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 1 month ago
Waiting on volume !
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 1 month ago
Just need some volume !
πŸ‘οΈ0
mikey4 mikey4 1 month ago
In 11,000 @0.63 here. Is this even close to accurate?

Here are the revenue forecasts for Azitra, Inc. (AZTR) for the next 5 years ΒΉ:
- *2024*: No forecast available
- *2025*: $3 million
- *2026*: $0
- *2027*: $0
- *2028*: $21 million
- *2029*: $93 million
- *2030*: $165 million
- *2031*: $229 million

Please note that these forecasts are subject to change and might not reflect the company's current financial situation.
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 1 month ago
I will love to see after-hours run, usually they are the best, patiently waiting !
πŸ‘οΈ0
Viewmont Viewmont 1 month ago
Yes, let's!
πŸ‘οΈ0
Viewmont Viewmont 1 month ago
https://finance.yahoo.com/news/azitra-inc-announces-q2-2024-222300234.html
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 1 month ago
Let’s have a nice squeeze $$$
πŸ‘οΈ0
Viewmont Viewmont 1 month ago
It's moving up! Let's go!
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 1 month ago
Loaded and ready
👍️ 1
Viewmont Viewmont 1 month ago
Yup! it should start going back up! https://schrts.co/ZVhEAaat
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 1 month ago
I like this

Completed a follow-on offering of $10 million in gross proceeds expected to provide cash runway into 2025. With the recent financing, the company anticipates announcing multiple clinical milestones
Strengthened global intellectual property portfolio with newly granted and allowed patents
Exhibited positive preclinical data from ATR-04 at the Society of Investigative Dermatology Annual Meeting
Presented positive preclinical data of ATR-12 and clinical design in Netherton Syndrome at the ASGCT Annual Meeting
Opened a Phase 1b clinical trial for ATR-12 for recruitment
👍️ 1
Viewmont Viewmont 1 month ago
$AZTR https://www.otcmarkets.com/filing/html?id=17752131&guid=y8O-kq652gSvB3h
πŸ‘οΈ0
Viewmont Viewmont 1 month ago
$AZTR Trying to move up! And there's a lot of room to do so! IMO.

BRANFORD, Conn., July 25, 2024--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions.

The updated release reads:

AZITRA, INC. ANNOUNCES CLOSING OF $10.0 MILLION PUBLIC OFFERING

Azitra, Inc. (NYSE American: AZTR) ("Company"), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the closing of its previously announced public offering of an aggregate of 6,665,000 shares of its common stock, and Class A warrants to purchase up to 13,330,000 shares of common stock, at a combined public offering price of $1.50 per share and accompanying warrants. The Class A warrant will have an initial exercise price of $1.50 per share, will be exercisable immediately upon issuance, and will expire on the fifth anniversary of the original issuance date.
πŸ‘οΈ0
Viewmont Viewmont 1 month ago
$AZTR https://schrts.co/pStTnWQN
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 1 month ago
Pressure building up !
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 1 month ago
A run of this level will be epic !
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 1 month ago
Nice thanks
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 1 month ago
40s on the way !
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 1 month ago
Not looking good, looks like 50s on the way, CEO dead silent !
πŸ‘οΈ0
PennyPusher786 PennyPusher786 2 months ago
Scam company. I'm 93 % down in only the past few months. Do not buy
πŸ‘οΈ0
PennyPusher786 PennyPusher786 2 months ago
Don't buy it
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
AZTR new 52 week low
πŸ‘οΈ0
herbied47 herbied47 2 months ago
https://ir.azitrainc.com/news-releases/news-release-details/azitra-inc-strengthens-global-intellectual-property-portfolio this was just days ago of which it hit $12 then. Shoot yes here!
πŸ‘οΈ0
PennyPusher786 PennyPusher786 2 months ago
Up 11% from the bottom though. A averaging down would've been nice for a quick 10% profit lol...

These pricks just did a share offering though. I have my eyes on GNS CEOS BNED for a near term move
πŸ‘οΈ0
PennyPusher786 PennyPusher786 2 months ago
Up 11% from the bottom though. A averaging down would've been nice for a quick 10% profit lol...

These pricks just did a share offering though. I have my eyes on GNS CEOS BNED for a near term move
πŸ‘οΈ0
PennyPusher786 PennyPusher786 2 months ago
They're doing it to secure their pockets. God forbid they should actually earn money for once.

Fricken credit lines, and share offerings. And nieve shareholders to foot the bill... The west is finished lol...
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 2 months ago
Same everywhere, I’m not sure how that even can be legal, check $SIDU they been doing this for the last 2 years, crazy !
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 2 months ago
https://scr.zacks.com/news/news-details/2024/AZTR-Get-Some-Skin-in-the-Game-article/default.aspx
πŸ‘οΈ0
PennyPusher786 PennyPusher786 2 months ago
I would consider a provEN OTC ticker at this point such that has room to grow like $CEOS

These nasdaq bioplays suck... pure reverse Splits and share offerings and barely ever a buyout or product that comes to fruition. Just CEOs and management using retail money to keep their income rolling
πŸ‘οΈ0
PennyPusher786 PennyPusher786 2 months ago
These morons ran a reverse split to get the share price out of pennies, then a share offering after a run up to $12.... and immediately dumped it under $1 again.

May God curse the management with for stealing money from share holders and lining their pockets.

Disgusting
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 2 months ago
Loading the 52WL, gambling here lol .
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
AZTR new 52 week low
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 2 months ago
New lows everywhere !
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 2 months ago
New 52WL after hours .96 !
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 2 months ago
https://www.businesswire.com/news/home/20240725675771/en/
πŸ‘οΈ0
PennyPusher786 PennyPusher786 2 months ago
I get the impression that thieves run this company
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
AZTR new 52 week low
πŸ‘οΈ0
PennyPusher786 PennyPusher786 2 months ago
They couldn't earn money the manly way eh.... Had to do it the Zalinsky Way "Give me Credit"
πŸ‘οΈ0
PennyPusher786 PennyPusher786 2 months ago
Personally, i think that was as high as it was gonna go for a lonnnnnnng while....lol....
πŸ‘οΈ0
PennyPusher786 PennyPusher786 2 months ago
Lol we shall see my friend
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock